IL17A and psoriasis: Further, biologics targeting the IL-17 receptor (brodalumab) or neutralizing IL-17 (ixekizumab and secukinumab) are highly effective in the treatment of psoriasis (Balato et al., 2017) and could be implemented in preclinical trials of PH.